Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-2 Wild-Type & Mutant Recombinant Proteins High purity (>95%), Endotoxin Controlled (<1 EU/ug). Sequence Verified. HEK293 Expressed for native glycosylation. |
View IL2 Products |
| Gene Delivery | IL-2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View IL2 Products |
| Benchmark Ab | Anti-IL-2 (Sequence of Aldesleukin / Biosimilar) Recombinant positive control antibody for benchmark binding and neutralization studies. |
View IL2 Products |
| Validator | IL-2 siRNA Set For knockdown verification and target specificity assays. |
View IL2 Products |
| Related Target A | IL-2RA (CD25) High-affinity alpha receptor subunit. Crucial for Treg-selective autoimmune therapy screening. |
View IL2RA Products |
| Related Target B | IL-2RB (CD122) Beta receptor subunit. Essential for "Not-Alpha" (CD25-independent) oncology drug design. |
View IL2RB Products |
| Related Target C | IL-2RG (CD132) Common gamma chain subunit. Required for functional heterotrimeric receptor complex assembly. |
View IL2RG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Screening CD25-biased vs. CD25-independent variants | High-purity monomeric IL-2RA, IL-2RB, and IL-2RG ECD-Fc recombinant proteins for precise SPR/BLI affinity metrics. |
| Subfamily off-target & cross-reactivity screening | Homolog panel proteins (IL-15, IL-7, IL-21 receptors) strictly verified by mass spectrometry and sequence analysis. |
| Lack of positive control benchmarks | Sequence-verified biosimilar antibodies (e.g., anti-IL2, anti-CD25) available to establish reliable assay baselines. |
| Inconsistent cell-based signaling assays | Lentiviral vectors for stable expression of CD25/CD122/CD132 complex to ensure robust pSTAT5 functional readout. |
Live IL-2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-2 therapeutics is intensifying, with major players shifting focus from traditional high-dose wild-type IL-2 therapies to engineered, bias-modulated modalities. While first-generation IL-2 (such as Aldesleukin) was plagued by severe toxicities like Vascular Leak Syndrome (VLS) and off-target Treg expansion, the next wave of R&D is targeting structural selectivity. In oncology, the industry is developing "Not-Alpha" (CD25-independent) IL-2 variants to selectively activate CD8+ T cells and NK cells without expanding immunosuppressive Tregs. Conversely, in autoimmune diseases, the focus is on CD25-biased, low-dose IL-2 or IL-2/Fc fusions that selectively expand Tregs to restore immune tolerance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| "Not-Alpha" IL-2 Mutants / Fusions | Sanofi (SAR444245), Alkermes (Nemvaleukin) | Solid Tumors (Melanoma, RCC) | Selectivity Assay (Need CD122/CD132 binding without CD25 interaction) |
| CD25-Biased IL-2 Fusions | Amgen (AMG 592), Eli Lilly (NKTR-358) | Autoimmune (SLE, Atopic Dermatitis) | Treg Selectivity Validation (Need high-purity CD25-Fc and stable reporter cell lines) |
| IL-2 Antibody-Cytokine Conjugates | Roche (RG6129), Immunocore | Oncology / Targeted Delivery | Conjugation & Internalization verification (Need sequence-verified antigens and functional receptors) |